TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17914135
Drug: Adequate vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate vitamin D stores (>34 ng/ml)
Study: 7779152
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg aciclovir tablet (test formulation)
Study: 7779152
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg aciclovir tablet (reference formulation)
Study: 7779152
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg aciclovir tablet (test formulation)
Study: 7779152
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg aciclovir tablet (reference formulation)
Study: 11198725
Drug: Flurbiprofen 8.75
Normalized name: flurbiprofen 8.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 8.75 mg
Study: 12658471
Drug: Eptifibatide plus
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide plus heparin
Study: 7535676
Drug: Colchicine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.6 mg twice daily)
Study: 6313561
Drug: Hemibody radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hemibody radiation (HBI) as a consolidating-maintenance agent
Study: 31343010
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid (α-LA) supplementation (1200 mg/day, 600 mg per capsule, 2 capsules daily)
Study: 31343010
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (2 capsules daily)
Study: 28891772
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy plus Hypnosis
Study: 26934084
Drug: Watermelon extract
Normalized name: watermelon extract 50 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermelon extract (6 g daily for 42 days)
Study: 26934084
Drug: Watermelon extract
Normalized name: watermelon extract 50 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermelon extract (6 g daily for 42 days) in carriers of the T allele (MTHFR C677T)
Study: 23082849
Drug: Total Disc
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Disc Replacement (TDR) with ProDisc-L
Study: 19497646
Drug: MCT/LCT lipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT/LCT lipid emulsion (M/L)
Study: 14630619
Drug: Sitaxsentan 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan 300 mg
Study: 11781553
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg atropine intravenously (i.v.)
Study: 7522392
Drug: Thick, energy-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thick, energy-dense porridge (4.09 kJ/g)
Study: 7522392
Drug: Traditional liquid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional liquid, low-density porridge (2.15 kJ/g)
Study: 12915681
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg/d)
Study: 16179584
Drug: Eplerenone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (200 mg.kg(‐1).d(‐1))
Study: 16179584
Drug: Aldosterone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone (250 nmol/L)
Study: 16179584
Drug: Eplerenone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (2 micromol/L)
Study: 11874386
Drug: Alosetron (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron (2 mg, single oral and intravenous doses)
Study: 2202512
Drug: Ceftizoxime 2
Normalized name: ceftizoxime 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime 2 gm intravenously every 12 hours with doxycycline 100 mg intravenously twice daily (Rx 1)
Study: 2202512
Drug: Cefoxitin 2
Normalized name: cefoxitin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin 2 gm intravenously every six hours with doxycycline 100 mg intravenously twice daily (Rx 2)
Study: 2202512
Drug: Ceftizoxime 2
Normalized name: ceftizoxime 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime 2 gm intravenously every eight hours with doxycycline 100 mg intravenously twice daily (Rx 3)
Study: 2202512
Drug: Clindamycin 900
Normalized name: clindamycin 900 MG in 6 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 900 mg intravenously every eight hours with a 2‐mg/kg loading dose of gentamicin followed by 1.5 mg/kg intravenously every eight hours (Rx 4)
Study: 31532808
Drug: Shorter distance
Normalized name: Cistanche tinctoria stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter distance to the treatment site
Study: 26486166
Drug: Ezetimibe/Simvastatin 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/Simvastatin 10/20 mg (ES10/20)
Study: 26486166
Drug: Statin dose-doubling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin dose-doubling (to S40 or A20)
Study: 23374898
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg (R10)
Study: 21554401
Drug: DFX-40 (deferasirox
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFX-40 (deferasirox 40 mg/kg/d for 6 months)
Study: 21554401
Drug: DFX-20 (deferasirox
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFX-20 (deferasirox 20 mg/kg/d for 6 months)
Study: 12630983
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TA) 220 micro g
Study: 12630983
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) 200 micro g
Study: 31332020
Drug: selinexor plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: selinexor plus low-dose dexamethasone
Study: 16245263
Drug: Metoclopramide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (30 mg)
Study: 9286225
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (5 g) with water (300 ml)
Study: 9286225
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (5 g) with glucose drink (300 ml/330 kcal)
Study: 9286225
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (5 g) with solid meal (530 kcal)
Study: 8364350
Drug: Fluoxetine 40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40 mg or 60 mg daily
Study: 8364350
Drug: Fluoxetine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (any dose)
Study: 3108527
Drug: CS-514 5
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-514 5 mg
Study: 3108527
Drug: CS-514 20
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-514 20 mg
Study: 3108527
Drug: CS-514 40
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-514 40 mg
Study: 3108527
Drug: CS-514 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-514 (all doses)
Study: 26596801
Drug: Intraperitoneal implantation
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal implantation of sustained-release 5-fluorouracil 600 mg as local chemotherapy
Study: 23332619
Drug: Doxycycline 40
Normalized name: Doxycycline 40 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 40 mg capsules orally once daily for 16 weeks
Study: 23332619
Drug: Placebo 40
Normalized name: placebo 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 40 mg capsules orally once daily for 16 weeks
Study: 2656042
Drug: MAb 96.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAb 96.5 as first infusion
Study: 2656042
Drug: MAb 96.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAb 96.5 as second infusion
Study: 2656042
Drug: ZME-018 as
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZME-018 as first infusion
Study: 2656042
Drug: ZME-018 as
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZME-018 as second infusion
Study: 31067356
Drug: Irinotecan with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan with vincristine (VI) followed by multi-agent chemotherapy for 44 weeks
Study: 31067356
Drug: Multi-agent chemotherapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-agent chemotherapy including tirapazamine (TPZ) for 31 weeks
Study: 31067356
Drug: Multi-agent chemotherapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-agent chemotherapy without VI and TPZ for 31 weeks
Study: 29746672
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg q2w plus MTX
Study: 29746672
Drug: Sarilumab 150
Normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 150 mg q2w plus MTX
Study: 27165711
Drug: Edoxaban 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 90 mg/day for 10 days followed by 60 mg/day
Study: 27165711
Drug: Parenteral anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral anticoagulation bridging to warfarin for 3 months
Study: 26280592
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment condition (AT; n = 31)
Study: 26280592
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment condition (CT; n = 31)
Study: 19808428
Drug: Higher HR
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher HR on in-treatment ECGs
Study: 19808428
Drug: Higher in-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher in-treatment HR
Study: 16650165
Drug: Desloratadine treatment
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine treatment for 4 weeks
Study: 2080486
Drug: 1 tablet
Normalized name: Ovral-21 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of althiazide (15 mg) and spironolactone (25 mg)
Study: 2080486
Drug: 2 tablets
Normalized name: Voydeya 150 MG Dose Card Pack, 4 Blister Cards, 42 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of althiazide (15 mg) and spironolactone (25 mg)
Study: 15725969
Drug: Methylphenidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.3 mg/kg
Study: 337493
Drug: Methylphenidate 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 1.0 mg/kg
Study: 29565195
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) agents - propess
Study: 29565195
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) agents - prostin
Study: 29565195
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propess and prostin
Study: 20357375
Drug: Sitagliptin (4-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (4-week treatment)
Study: 16155380
Drug: Milrinone in
Normalized name: milrinone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone in combination with inhaled nitric oxide (iNO)
Study: 12862328
Drug: Malarone (atovaquone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malarone (atovaquone 250 mg/proguanil 100 mg)
Study: 12862328
Drug: Primaquine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (30 mg of base)
Study: 10979164
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment on postoperative days 2 through 5
Study: 3555355
Drug: Dakin's solution
Normalized name: Sodium Hypochlorite 0.5% Topical application Solution [DAKIN'S SOLUTION FULL STRENGTH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dakin's solution (chloramine‐T)‐soaked wet‐to‐dry dressings
Study: 28811354
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg QD
Study: 28811354
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg QD
Study: 22076246
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dexamphetamine
Study: 22076246
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dexamphetamine + 0.8 g/kg alcohol
Study: 18767576
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group with oral administration of Qianliekang tablets
Study: 9891521
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with carboplatin and ifosfamide (11 patients)
Study: 9891521
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with carboplatin and paclitaxel (3 patients)
Study: 9891521
Drug: No neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neoadjuvant chemotherapy (6 patients with no change)
Study: 2691483
Drug: Single pre-operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single pre-operative dose of 2.2 g amoxycillin/clavulanate
Study: 2691483
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1.5 g cefuroxime plus 0.5 g metronidazole
Study: 371733
Drug: Conventional compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional compound (methylglucamine‐ioxitalamate)
Study: 28606661
Drug: VR training
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR training using Xbox Kinect plus conventional physical therapy (30 minutes each)
Study: 28606661
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy only (30 minutes)
Study: 28606661
Drug: VR training
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR training using Xbox Kinect plus conventional physical therapy
Study: 21418260
Drug: Pancrelipase delayed-release
Normalized name: Pancrelipase Delayed-Release Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancrelipase delayed-release capsules (Creon) at a mean dose of 186960±74640 lipase units/day
Study: 21418260
Drug: Pancrelipase delayed-release
Normalized name: Pancrelipase Delayed-Release Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancrelipase delayed-release capsules (Creon)
Study: 15084794
Drug: Donepezil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (10 mg daily) plus cognitive training (images of everyday life and reminiscent music, 3 sessions per week for 12 months)
Study: 11284571
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment using a Herbert bone screw
Study: 11284571
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment using a cast
Study: 2519941
Drug: 1 gram
Normalized name: guar gum 1 gram ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram of nafcillin in 10 mL of saline as an intravenous (IV) bolus
Study: 2519941
Drug: 1 gram
Normalized name: guar gum 1 gram ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram of nafcillin in 50 mL of saline as a slow IV infusion over 15 minutes
Study: 2519941
Drug: No nafcillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No nafcillin administration (Control group)
Study: 31619654
Drug: Ultra-high hydrostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-high hydrostatic pressurized brown rice (UHHPBR) intake group (n=20) consuming 100 g of UHHPBR and 100 g of white rice (WR) per day for 12 months
Study: 31619654
Drug: White rice
Normalized name: White Rice
Approvals — FDA: no, EMA: no, PMDA: no
Description: White rice (WR) intake group (n=20) consuming 200 g of WR per day for 12 months
Study: 28301687
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (OG; n=20) applied at the point of greatest pain, three times per week for a total of six sessions.
Study: 28301687
Drug: Sham ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ozone therapy (PG; n=20) applied at the point of greatest pain, three times per week for a total of six sessions.
Study: 28301687
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (OG) at 3 months (T2) for temporal muscle PPT.
Study: 28301687
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (OG) at 3 months (T2) for masseter muscle PPT.
Study: 28301687
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (OG) at 3 months (T2) for lateral pole PPT.
Study: 28301687
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (OG) for right lateral excursion at 3 months (T2).
Study: 28301687
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (OG) for overall VAS scores from baseline to 3 months.
Study: 25894894
Drug: JNJ-38893777 (doses:
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-38893777 (doses: 5, 15, 45, 125, 250, or 500 mg)
Study: 25894894
Drug: JNJ-38893777 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-38893777 (250 mg in fasting state and 250 mg, 375 mg, or 500 mg in high-fat fed state)
Study: 21429223
Drug: Single intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intradermal sterile water injection (SWI) technique
Study: 21429223
Drug: Four intradermal
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four intradermal sterile water injection (SWI) technique
Study: 15220018
Drug: Glimepiride +
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride + Pioglitazone (G + P)
Study: 15220018
Drug: Glimepiride +
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride + Rosiglitazone (G + R)
Study: 9640189
Drug: Latanoprost monotherapy
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost monotherapy (50 micrograms/ml)
Study: 9640189
Drug: Dipivefrin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipivefrin monotherapy (1 mg/ml)
Study: 9640189
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of latanoprost and dipivefrin
Study: 7979527
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of cromoglycate three times a day by wet nebulisation (n = 16)
Study: 1147500
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam preoperatively
Study: 31743136
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 to 3 mg/kg)
Study: 31743136
Drug: Etomidate (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.2 to 0.3 mg/kg)
Study: 24060106
Drug: Attention-control group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention-control group (bi-monthly telephone contact)
Study: 15316094
Drug: Everolimus 0.75
Normalized name: everolimus 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 0.75 mg/day
Study: 15316094
Drug: Everolimus 2.5
Normalized name: everolimus 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 2.5 mg/day
Study: 21232120
Drug: Everolimus 5
Normalized name: everolimus 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 5 mg/day
Study: 9109044
Drug: Tirilazad mesylate
Normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad mesylate 10.0 mg/kg/day for 5 days
Study: 3539631
Drug: Ambroxol (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (90 mg orally for 14 days)
Study: 29692607
Drug: Indacaterol/glycopyrronium (IND/GLY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg
Study: 24525630
Drug: Bilateral suprazygomatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral suprazygomatic maxillary nerve block with 0.15 ml/kg of 0.2% ropivacaine
Study: 22632908
Drug: 0.9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg/kg intravenous recombinant tissue plasminogen activator (rt-PA)
Study: 20710058
Drug: JTK-652 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTK-652 (100 mg three times daily for 4 weeks)
Study: 17050021
Drug: Imagery rehearsal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagery rehearsal in addition to normal physical therapy (12 individual sessions)
Study: 11904107
Drug: Calcium (1
Normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1 g/d, n = 111)
Study: 1455195
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Cyclosporin
Study: 1455195
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Cyclosporin
Study: 30829137
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (50,000 IU weekly for 16 weeks)
Study: 29986492
Drug: Fortified corn-soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified corn-soy blend (CSB+) with multiple-micronutrient supplement (CSB+UNIMMAP)
Study: 23802706
Drug: Q8003 (morphine/oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q8003 (morphine/oxycodone combination) 12 mg/8 mg